Showing results (471-480 of 782) with videos related to

Sort By:
Pageof 79
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Cancer|October 17, 2023
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myelomaWenqiang Yan, Jingyu Xu, Huishou Fan, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
British Journal of Haematology|April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myelomaYutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Blood|January 30, 2010
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemiaAldo M Roccaro, Antonio Sacco, Monette Aujay, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|August 7, 2024
Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studiesDanka Cholujova, Zdenka Lukacova Bujnakova, Erika Dutkova, et al.
Cancer Research|March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathwayJian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Pageof 79